Susquehanna International Group
CRSP icon

Susquehanna International Group’s CRISPR Therapeutics CRSP Stock Holding History

Susquehanna International Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.9M Buy
566,400
+16,000
+3% +$844K ﹤0.01% 1871
2025
Q4 		$28.9M Sell
550,400
-600
-0.1% -$35.9K ﹤0.01% 1854
2025
Q3 		$35.7M Sell
551,000
-256,100
-32% -$14.7M ﹤0.01% 1629
2025
Q2 		$39.3M Buy
807,100
+463,700
+135% +$17.9M 0.01% 1350
2025
Q1 		$11.7M Buy
343,400
+178,100
+108% +$7.55M ﹤0.01% 2323
2024
Q4 		$6.51M Sell
165,300
-98,100
-37% -$4.63M ﹤0.01% 3208
2024
Q3 		$12.4M Sell
263,400
-88,600
-25% -$4.5M ﹤0.01% 2348
2024
Q2 		$19M Sell
352,000
-379,200
-52% -$21.9M ﹤0.01% 1782
2024
Q1 		$49.8M Sell
731,200
-182,400
-20% -$13.1M 0.01% 1031
2023
Q4 		$57.2M Buy
913,600
+528,700
+137% +$29.2M 0.01% 963
2023
Q3 		$17.5M Sell
384,900
-33,500
-8% -$1.73M ﹤0.01% 1888
2023
Q2 		$23.5M Buy
418,400
+183,200
+78% +$10.4M ﹤0.01% 1575
2023
Q1 		$10.6M Sell
235,200
-198,700
-46% -$9.65M ﹤0.01% 2362
2022
Q4 		$17.6M Sell
433,900
-183,800
-30% -$9.75M ﹤0.01% 1655
2022
Q3 		$40.4M Buy
617,700
+73,300
+13% +$5.31M 0.01% 928
2022
Q2 		$33.1M Buy
544,400
+196,200
+56% +$11.5M 0.01% 1084
2022
Q1 		$21.9M Buy
348,200
+115,400
+50% +$7.25M ﹤0.01% 1638
2021
Q4 		$17.6M Buy
232,800
+27,500
+13% +$2.4M ﹤0.01% 2012
2021
Q3 		$23M Sell
205,300
-189,800
-48% -$23.8M ﹤0.01% 1835
2021
Q2 		$64M Buy
395,100
+57,900
+17% +$7.04M 0.01% 1028
2021
Q1 		$41.1M Buy
337,200
+14,800
+5% +$2.23M 0.01% 1254
2020
Q4 		$49.4M Buy
322,400
+17,800
+6% +$2.1M 0.01% 1016
2020
Q3 		$25.5M Sell
304,600
-13,100
-4% -$1.16M ﹤0.01% 1286
2020
Q2 		$23.3M Buy
317,700
+145,700
+85% +$8.52M 0.01% 1301
2020
Q1 		$7.29M Sell
172,000
-11,100
-6% -$573K ﹤0.01% 2111
2019
Q4 		$11.2M Sell
183,100
-15,800
-8% -$863K ﹤0.01% 1974
2019
Q3 		$8.15M Buy
198,900
+25,200
+15% +$1.2M ﹤0.01% 2188
2019
Q2 		$8.18M Buy
173,700
+6,300
+4% +$252K ﹤0.01% 2109
2019
Q1 		$5.98M Buy
167,400
+57,200
+52% +$1.98M ﹤0.01% 2255
2018
Q4 		$3.15M Sell
110,200
-75,600
-41% -$2.63M ﹤0.01% 2870
2018
Q3 		$8.24M Sell
185,800
-53,900
-22% -$2.82M ﹤0.01% 2131
2018
Q2 		$14.1M Buy
239,700
+139,000
+138% +$7.92M ﹤0.01% 1612
2018
Q1 		$4.6M Buy
100,700
+44,300
+79% +$1.83M ﹤0.01% 2644
2017
Q4 		$1.32M Buy
+56,400
New +$1.07M ﹤0.01% 4680

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group's CRSP Position: Q1 2026 in Review

Susquehanna International Group reduced its CRISPR Therapeutics (CRSP) stake by 31% in Q1 2026, selling an estimated $13.7M and leaving 593,406 shares worth $28.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

Susquehanna International Group first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $57M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Susquehanna International Group held 593,406 shares of CRISPR Therapeutics worth $28.2M as of Q1 2026.
  • Susquehanna International Group sold 260,565 CRISPR Therapeutics shares in Q1 2026, an estimated $13.7M.
  • CRISPR Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1806 holding.
  • Susquehanna International Group first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
  • Susquehanna International Group's CRISPR Therapeutics position peaked at $57M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.